Most Read Articles
Dr. Joseph Delano Fule Robles, 12 Feb 2019

A team of investigators from the University of Hong Kong (HKU) identified high-risk Epstein Barr virus (EBV) variants present in 97 percent of nasopharyngeal carcinoma (NPC) cases.

5 days ago
New drug applications approved by US FDA as of 01- 15 February 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Pearl Toh, 23 Aug 2018
Restoration of CD4/CD8 ratio on combination antiretroviral therapy (cART) was associated with decreased risk of Kaposi sarcoma (KS) while baseline CD8 count was related to non-Hogkin lymphoma (NHL) risk in people living with HIV (PLHIV) who had achieved viral suppression on cART, according to the COHERE* study presented at the AIDS International Conference (AIC) 2018.
Roshini Claire Anthony, 16 Jan 2019

A once-daily oral dose of sofosbuvir and velpatasvir for 12 weeks leads to sustained virological response (SVR) in a majority of patients with chronic hepatitis C virus (HCV) infection, according to an Asian study. However, the efficacy of this regimen may be reduced in patients with HCV genotype 3b with cirrhosis.

HIV incidence rising in young men, MSM of colour

30 Mar 2018

A US study suggests that expanding HIV screening to reduce undiagnosed infections and increasing access to care and treatment to achieve viral suppression are important to lessen HIV transmission. It is also imperative that prevention methods, such as condoms and pre-exposure prophylaxis, be easily accessed, particularly among young men who have sex with men (MSM) and MSM of colour.

There was a 14.8-percent decrease in modeled HIV incidence (from 45,200 infections in 2008 to 38,500 in 2015) overall and among all transmission risk groups, except MSM.

HIV incidence rose by 3.1 percent (95 percent CI, 1.6–4.5 percent) per year among Hispanic/Latino MSM (from 6,300 infections in 2008 to 7,900 in 2015), decreased by 2.7 percent (–3.8 to –1.5 percent) per year among white MSM (from 8,800 infections in 2008 to 7,100 in 2015) and remained stable among black MSM at about 10,000 infections.

While HIV incidence decreased by 3.0 percent (–4.2 percent to –1.8 percent) and 4.7 percent (–6.2 to –3.1 percent) per year among MSM aged 13–24 years and those aged 35–44 years, respectively, it increased by 5.7 percent (4.4–7.0 percent) per year (from 6,900 infections in 2008 to 10,000 in 2015) among MSM aged 25–34 years.

“The percentage of undiagnosed HIV infections was higher among black, Hispanic/Latino, and younger MSM than white and older MSM, respectively,” the investigators said.

Individuals aged 13 years with diagnosed HIV infection were included in this cross-sectional analysis. The investigators used data on HIV diagnoses and the first CD4 test result after diagnosis to model HIV incidence and prevalence as well as the percentage of undiagnosed HIV infections from 2008 to 2014 based on a well-characterized CD4 depletion model.

The study was limited by the assumptions of the CD4 depletion model and variability of CD4 values, according to the investigators.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 12 Feb 2019

A team of investigators from the University of Hong Kong (HKU) identified high-risk Epstein Barr virus (EBV) variants present in 97 percent of nasopharyngeal carcinoma (NPC) cases.

5 days ago
New drug applications approved by US FDA as of 01- 15 February 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Pearl Toh, 23 Aug 2018
Restoration of CD4/CD8 ratio on combination antiretroviral therapy (cART) was associated with decreased risk of Kaposi sarcoma (KS) while baseline CD8 count was related to non-Hogkin lymphoma (NHL) risk in people living with HIV (PLHIV) who had achieved viral suppression on cART, according to the COHERE* study presented at the AIDS International Conference (AIC) 2018.
Roshini Claire Anthony, 16 Jan 2019

A once-daily oral dose of sofosbuvir and velpatasvir for 12 weeks leads to sustained virological response (SVR) in a majority of patients with chronic hepatitis C virus (HCV) infection, according to an Asian study. However, the efficacy of this regimen may be reduced in patients with HCV genotype 3b with cirrhosis.